Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de las Nieves (16)

2024

  1. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study

    Atherosclerosis, Vol. 393

  2. Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study

    The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 9, pp. 643-652

  3. Review of the allocation criteria for heart transplant in Spain in 2023. SEC-Heart Failure Association/ONT/SECCE consensus document

    Revista Espanola de Cardiologia, Vol. 77, Núm. 1, pp. 69-78

2023

  1. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study

    Circulation, Vol. 147, Núm. 19, pp. 1436-1443

  2. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

    International Journal of Infectious Diseases, Vol. 137, pp. 134-143

  3. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study

    European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 320-328

2022

  1. A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort

    European Journal of Preventive Cardiology, Vol. 29, Núm. 5, pp. 795-801

  2. Outpatient Parenteral Antibiotic Treatment vs Hospitalization for Infective Endocarditis: Validation of the OPAT-GAMES Criteria

    Open Forum Infectious Diseases, Vol. 9, Núm. 9

  3. Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics

    Journal of Clinical Medicine, Vol. 11, Núm. 5

2021

  1. Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience

    Journal of Clinical Lipidology, Vol. 15, Núm. 4, pp. 584-592

2020

  1. Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 4, pp. 313-323

  2. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 828-834

2019

  1. Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study

    Journal of Clinical Lipidology, Vol. 13, Núm. 6, pp. 989-996

  2. SECTCV recommendations document in cardiovascular surgery. 2019 updating of the standards in organization, professional activity, quality of health-care, and training in the specialty

    Cirugia Cardiovascular, Vol. 26, Núm. 2, pp. 104-123

2018

  1. Diagnosis, management and mortality in acute aortic syndrome: results of the Spanish Registry of Acute Aortic Syndrome (RESA-II)

    European heart journal. Acute cardiovascular care, Vol. 7, Núm. 7, pp. 602-608

2002

  1. Heterozygous familial hypercholesterolemia in Spain. Description of 819 non related cases

    Medicina Clinica, Vol. 118, Núm. 13, pp. 487-492